Knowing that the hostile microenvironment is part of the resistance system of CAR T-cell therapy in CRC, a study evaluated the implication of Interferon-alpha/beta receptor alpha chain (IFNAR1). The gene discussed is IFNAR1; the disease is colorectal carcinoma.